Participants 101 157 5
women with ErbB2 overexpressing metastatic breast cancer
Participants 569 598 4
women with HER2-positive MBC.
Participants 599 927 5
In this open-label, multicenter, phase II study, eligible patients (N = 112) were randomized 2:1 to lapatinib plus vinorelbine [(N = 75) 1,250 mg orally once daily (QD) continuously plus 20 mg/m(2)/day intravenously] or lapatinib plus capecitabine [(N = 37) 1,250 mg orally QD continuously plus 2,000 mg/m(2)/day orally, 2 doses
Participants 1850 1887 3
patients with HER2-overexpressing MBC
